title: Promus Premier versus Xience V and Taxus Liberte in contemporary United States practice (REWARDS premier registry).
abstract: OBJECTIVE
  Drug-eluting stents (DES) reduce in-stent restenosis and repeat revascularization in comparison to bare metal stents. Individual DES vary, however, in regard to rates of restenosis and stent thrombosis; they also differ in regard to their platform and physical characteristics. The Promus Premier was designed to improve the performance of the Promus Element, with respect to conformability, trackability, and avoidance of longitudinal stent deformation; there is little published data, however, on clinical outcomes with Promus Premier.
  
  
  METHODS
  We performed a registry study that compared 952 patients who underwent percutaneous coronary intervention with Promus Premier to 595 patients who received Taxus Liberte and 600 patients who received Xience V for a variety of indications. The primary endpoint was a composite of all-cause mortality, definite or probable stent thrombosis, myocardial infarction, and target vessel revascularization (TVR-MACE). Kaplan-Meier analysis and Cox proportional hazards regression were performed in order to compare the three stents in regard to outcomes at 1year.
  
  
  RESULTS
  Procedural success was highest with Premier (99.4%) when compared to Xience V (98.0%) and Taxus Liberte (97.3%; p<0.001). Unadjusted survival analysis showed that TVR-MACE was less frequent with Premier in comparison to Taxus Liberte (p=0.003), and similar frequency in comparison to Xience V (p=0.16). Following multivariable adjustment, and using Xience V as the reference, there was only a borderline association of Promus Premier and lower rates of TVR-MACE (HR 0.69, 95% CI 0.45-1.04; p=0.075).
  
  
  CONCLUSIONS
  Promus Premier demonstrates excellent procedural success rates and real-world outcomes that are similar to Xience V.
authors.affiliation: MedStar Cardiovascular Research Network/MedStar Washington Hospital Center, Washington, DC, USA.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Gaglia
authors.affiliation: Grand Strand Regional Medical Center, Myrtle Beach, SC, USA.
authors.forename: Randy
authors.initials: R
authors.lastname: Goodroe
authors.affiliation: Prairie Education and Research Cooperative, Springfield, IL, USA.
authors.forename: Greg
authors.initials: G
authors.lastname: Mishkel
authors.affiliation: West Virginia University Heart Institute, Morgantown, WV, USA.
authors.forename: Wassim
authors.initials: W
authors.lastname: Gharib
authors.affiliation: Sinai Hospital, Baltimore, MD, USA.
authors.forename: Ali
authors.initials: A
authors.lastname: Tabrizchi
authors.affiliation: Columbia University Medical Center, New York, NY, USA.
authors.forename: Tamim
authors.initials: T
authors.lastname: Nazif
authors.affiliation: Medstar Union Memorial Hospital, Baltimore, MD, USA.
authors.forename: John
authors.initials: J
authors.lastname: Wang
authors.affiliation: Geisinger Medical Center, Danville, PA, USA.
authors.forename: Thomas
authors.initials: T
authors.lastname: Scott
authors.affiliation: Charlotte Heart Research Group, Port Charlotte, FL, USA.
authors.forename: Mario
authors.initials: M
authors.lastname: Lopez
authors.affiliation: Medical University of South Carolina, Charleston, SC, USA.
authors.forename: Daniel
authors.initials: D
authors.lastname: Steinberg
authors.affiliation: MedStar Cardiovascular Research Network/MedStar Washington Hospital Center, Washington, DC, USA.
authors.forename: Jiaxiang
authors.initials: J
authors.lastname: Gai
authors.affiliation: MedStar Cardiovascular Research Network/MedStar Washington Hospital Center, Washington, DC, USA.
authors.forename: Rebecca
authors.initials: R
authors.lastname: Torguson
authors.affiliation: MedStar Cardiovascular Research Network/MedStar Washington Hospital Center, Washington, DC, USA. Electronic address: ron.waksman@medstar.net.
authors.forename: Ron
authors.initials: R
authors.lastname: Waksman
mesh_terms: D000368:Aged; D002317:Cardiovascular Agents / Q000008:administration & dosage; D016009:Chi-Square Distribution; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000628:therapy*; D003328:Coronary Thrombosis / Q000209:etiology; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000008:administration & dosage; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000209:etiology; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000295:instrumentation*; D016016:Proportional Hazards Models; D011474:Prosthesis Design; D012042:Registries; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States
chemical_list: D002317:Cardiovascular Agents; D000068338:Everolimus
keywords: Coronary artery disease; Drug-eluting stent; Everolimus; Stent thrombosis